RESEARCH · MOTS-C · VASCULAR, HEART AND KIDNEY MODELS
MOTS-c in Cardiovascular and Kidney Research: Endothelium, Vascular Calcification, Heart Failure, Ischaemia and Kidney Disease
PurixLab’s MOTS-C 10mg is a research vial of MOTS-c, the 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. Our earlier articles cover obesity and diabetes models, including the diabetic heart, lung injury and sepsis and circulating levels in humans and assay limits. This article looks at blood vessels, the non-diabetic heart and the kidney: vascular calcification, pressure-overload heart failure, ischaemia-reperfusion of the isolated heart, exercise adaptation, and the patient cohorts in coronary and kidney disease where MOTS-c has been measured. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Endothelial function: where the cardiovascular interest began
The first cardiovascular study combined a human cohort with rodent vessels. Forty patients with recurrent angina but no structural coronary lesions underwent coronary endothelial function testing with acetylcholine. Plasma MOTS-c, measured by ELISA, was lower in the 20 with endothelial dysfunction than in the 20 with normal function, and correlated with both microvascular and epicardial endothelial responses [1]. In organ-chamber experiments, MOTS-c had no direct vasoactive effect, but pretreating aortic rings from rats or from mice with renal artery stenosis improved their relaxation to acetylcholine [1]. A letter published in the same journal later in 2018, indexed as a comment, is titled “MOTS-c attenuates endothelial dysfunction via suppressing the MAPK/NF-κB pathway” [2]. It has no abstract in PubMed, so we do not summarise its data.
Vascular calcification
In rats given vitamin D3 plus nicotine, a standard model of arterial calcification, MOTS-c significantly attenuated calcification. Treated animals showed higher phosphorylated AMPK and lower expression of the angiotensin II type 1 and endothelin B receptors, and the authors also reported effects on secondary myocardial remodelling [3]. This remains, to our knowledge, a single study in a single model.
The non-diabetic heart
Pressure overload. Transverse aortic constriction in mice forces the left ventricle to pump against a narrowed aorta and leads to heart failure. MOTS-c delivered by subcutaneous osmotic pump attenuated cardiac dysfunction and remodelling, reduced inflammatory responses and raised antioxidant capacity, with AMPK pathway activation. In H9C2 cardiac cells, over-expression of MOTS-c activated AMPK and protected against hydrogen peroxide-induced apoptosis [4].
Ischaemia-reperfusion of the isolated heart. Two 2026 studies from one Indian group used Langendorff-perfused rat hearts subjected to 30 minutes of global ischaemia and 60 minutes of reperfusion. In the first, MOTS-c added during early reperfusion gave a 73% reduction in infarct size at the best concentration tested and a 65% reduction in lactate dehydrogenase release, alongside improved antioxidant enzymes and lower pro-apoptotic gene expression; molecular docking was used to propose interaction partners [5]. The second examined two mitochondrial subpopulations and found partial preservation of electron transport enzyme activity, membrane potential and mtDNA copy number in both [6]. The authors of the first study note that the isolated-heart model lacks systemic influences and that broader pharmacokinetic work is needed [5].
Infarct repair with a biomaterial. A 2027 study conjugated MOTS-c to a self-assembling peptide to make a hydrogel that carried transplanted mitochondria. The gel extended the survival of isolated mitochondria, enhanced their uptake by macrophages through AMPK, and shifted macrophage metabolism away from pro-inflammatory glycolysis. In a rat infarction model the combined system improved cardiac function [7]. Because MOTS-c is one part of a composite material, this does not isolate the peptide’s own effect.
Exercise and the healthy heart
Two rat studies examined MOTS-c alongside aerobic training. Pressure-volume catheter measurements showed that MOTS-c improved myocardial mechanical efficiency and systolic function in exercised rats [8]. A follow-up found that MOTS-c and aerobic exercise each increased heart weight and heart weight index and improved contractility indices, with increased ErbB4 and Gata4 and decreased C/EBPβ; NRG1 mRNA rose with exercise but not significantly with MOTS-c [9]. The authors interpret this as physiological rather than pathological hypertrophy, but the distinction rests on a limited set of markers.
Human cardiovascular cohorts point in different directions
Observational studies of circulating MOTS-c in heart disease do not agree on direction:
- In stable angina, MOTS-c was lower in ninety-two patients with coronary artery disease than in ninety-two with normal coronary arteries [10].
- In a 400-person case-control study, serum MOTS-c was higher in acute coronary syndrome and correlated positively with a marker of oxidative stress; in vitro, oxidative stress induced MOTS-c [11].
- In 72 patients with acute myocardial infarction treated by percutaneous coronary intervention, lower postoperative peripheral MOTS-c was associated with reperfusion injury, while preoperative and intracoronary levels did not differ between groups; the area under the curve was 0.648 [12].
One reading is that MOTS-c is low in chronic vascular dysfunction and rises acutely as a stress response. Another is that ELISA-based measurements in different populations are not comparable. Neither has been tested directly.
The kidney
Chronic kidney disease. In patients with stage 5 chronic kidney disease, MOTS-c was reduced in both skeletal muscle and serum compared with age-matched controls, whereas circulating humanin, a related mitochondrial peptide, was increased [13]. In 94 patients on haemodialysis, by contrast, MOTS-c was higher than in controls and higher still in those who died or had a cardiovascular event during follow-up; adding it to risk models modestly improved prediction [14].
Peritoneal dialysis. Two pilot studies of 32 patients measured MOTS-c in serum, urine and dialysate. Patients at very high risk of sarcopenia had lower serum and higher dialysate MOTS-c, suggesting peritoneal loss of the peptide [15]. In the same kind of cohort, urinary MOTS-c correlated inversely with an oxidative stress marker but positively with arterial stiffness, while dialysate MOTS-c correlated inversely with arterial stiffness [16]. These mixed correlations in small samples are hypothesis-generating at best.
Diabetic kidney disease. In children with type 1 diabetes, serum MOTS-c was lower than in healthy children but did not differ by albuminuria, hyperfiltration or eGFR decline, and was not predictive of diabetic kidney disease [17]. In db/db mice, MOTS-c preserved the urinary albumin-to-creatinine ratio, reduced tubular injury, lipid deposits and senescence markers, and promoted lipophagy by downregulating LARS1; an autophagy inhibitor largely reversed the protection [18].
A counterpoint. In adipose-derived mesenchymal stromal cells from people with obesity, MOTS-c restored intracellular levels and activated AMPK but reduced proliferation and increased senescence-associated genes and TNF-α. In a mouse renal artery stenosis model, MOTS-c-pretreated cells failed to improve renal perfusion or fibrosis, and pretreatment blunted the benefit of lean-donor cells [19]. AMPK activation, the mechanism invoked in most of the studies above, did not translate into repair in this setting.
What remains open
- Small, single-group animal studies. Calcification, pressure overload and isolated-heart results each rest on one group’s work [3,4,5].
- AMPK as a catch-all. Many papers report AMPK activation, but few test whether blocking it removes the effect, and one cell study shows AMPK activation without functional benefit [19].
- Biomarker direction. Human studies report lower, higher or unchanged MOTS-c depending on the condition and population [10,11,14,13].
- Kidney handling. Urinary and dialysate measurements show that the kidney and dialysis membranes handle the peptide, but its renal clearance and how kidney function affects circulating levels have not been characterised [15,16].
MOTS-C 10mg at PurixLab
MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/mots-c-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Qin Q, Delrio S, Wan J, et al. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int J Cardiol. 2018;254:23-27. PubMed 29242099 · doi:10.1016/j.ijcard.2017.12.001
- Li H, Ren K, Jiang T, et al. MOTS-c attenuates endothelial dysfunction via suppressing the MAPK/NF-κB pathway. Int J Cardiol. 2018;268:40. PubMed 30041797 · doi:10.1016/j.ijcard.2018.03.031
- Wei M, Gan L, Liu Z, et al. Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway. Cardiorenal Med. 2020;10(1):42-50. PubMed 31694019 · doi:10.1159/000503224
- Zhong P, Peng J, Hu Y, et al. Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice. J Cell Mol Med. 2022;26(21):5369-5378. PubMed 36156853 · PMC9639045 · doi:10.1111/jcmm.17551
- Santhanam SS, Jayaraman S, Kurian GA. Exogenous MOTS-c mitigates myocardial ischemia-reperfusion injury: experimental and in silico evidence from rat heart models. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(7):9969-9984. PubMed 41593376 · doi:10.1007/s00210-026-05018-0
- Santhanam SS, Jayaraman S, Rajesh SS, et al. MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia reperfusion injury. Mol Biol Rep. 2026;53(1):873. PubMed 42228044 · doi:10.1007/s11033-026-12064-7
- Li H, Zhang Y, Jian Y, et al. Mitochondria-derived peptide hydrogel augments mitochondrial transplantation for promoting cardiac repair via macrophage metabolic reprogramming. Bioact Mater. 2027;67:458-476. PubMed 42633281 · PMC13499492 · doi:10.1016/j.bioactmat.2026.06.010
- Yuan J, Wang M, Pan Y, et al. The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats. Sci Rep. 2021;11(1):20077. PubMed 34635713 · PMC8505603 · doi:10.1038/s41598-021-99568-3
- Yuan J, Xu B, Ma J, et al. MOTS-c and aerobic exercise induce cardiac physiological adaptation via NRG1/ErbB4/CEBPβ modification in rats. Life Sci. 2023;315:121330. PubMed 36584915 · doi:10.1016/j.lfs.2022.121330
- Yaşar E, Çakmak T, Bayramoğlu A, et al. MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease. Eur Rev Med Pharmacol Sci. 2022;26(16):5676-5682. PubMed 36066139 · doi:10.26355/eurrev_202208_29501
- Cao P, Wang B, Zhang N, et al. Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study. J Am Heart Assoc. 2025;14(24):e041905. PubMed 41368821 · PMC12826893 · doi:10.1161/JAHA.125.041905
- Peng L, Li Y, Duan X, et al. The Association Between Serum MOTS-c Levels and Myocardial Ischemia-Reperfusion Injury in Patients with Acute Myocardial Infarction: A Cross-Sectional Study. Biomedicines. 2026;14(4):918. PubMed 42072458 · PMC13113351 · doi:10.3390/biomedicines14040918
- Liu C, Gidlund EK, Witasp A, et al. Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease. Am J Physiol Renal Physiol. 2019;317(5):F1122-F1131. PubMed 31432706 · doi:10.1152/ajprenal.00202.2019
- Bolignano D, Greco M, Presta P, et al. The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study. Blood Purif. 2024;53(10):824-837. PubMed 39111290 · doi:10.1159/000540303
- Zicarelli M, Greco M, Roumeliotis S, et al. MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study. Medicina (Kaunas). 2025;61(2):322. PubMed 40005438 · PMC11857303 · doi:10.3390/medicina61020322
- Musolino M, Roumeliotis A, Roumeliotis S, et al. MOTS-c is associated with oxidative stress and arterial stiffness in peritoneal dialysis patients: a pilot study. Int Urol Nephrol. 2026;58(11):4997-5004. PubMed 42126770 · doi:10.1007/s11255-026-05198-x
- Girişgen İ, Altıncık SA, Avcı E, et al. Could MOTS-c Levels in Children with Type 1 Diabetes Mellitus Be an Indicator for Early Diabetic Kidney Disease? J Clin Res Pediatr Endocrinol. 2025;17(2):168-175. PubMed 39711006 · PMC12118320 · doi:10.4274/jcrpe.galenos.2024.2024-5-6
- Wang J, Luo S, Han Y, et al. Mots-c attenuates diabetic nephropathy by downregulating LARS1 to promote lipophagy and suppress tubular senescence. Biochem Pharmacol. 2026;254(Pt 4):118572. PubMed 42918312 · doi:10.1016/j.bcp.2026.118572
- Xing L, Lu B, Zhu X, et al. Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells. Inflamm Regen. 2026;46(1):35. PubMed 42324588 · PMC13536784 · doi:10.1186/s41232-026-00431-7